CUSABIO undertook a stepwise approach to produce the CEACAM5/CEACAM6 recombinant monoclonal antibody. Initially, B cells were isolated from the spleen of an immunized animal, utilizing recombinant human CEACAM5/CEACAM6 protein as the immunogen during the immunization process. Subsequently, RNA was extracted from the B cells and reversely transcribed into cDNA. Using the cDNA as a template, the gene encoding the CEACAM5/CEACAM6 antibody was extended with a degenerate primer and inserted into a vector. This recombinant vector was then transfected into host cells to enable antibody expression. The CEACAM5/CEACAM6 recombinant monoclonal antibodies were harvested from the cell culture supernatant and purified via affinity chromatography. To validate this antibody's specificity, it underwent testing in ELISA to confirm its reactivity with human CEACAM5 and CEACAM6 proteins.
Email: support@cusabio.com
Distributors Worldwide